We have recently performed the first comprehensive study of the potential immunosuppressive role of soluble CD40L (sCD40L). In addition, we demonstrated that serum sCD40L can potentially be used as an indicator of response to anticancer therapy, and/or to better identify those patients who would have best chances to benefit from tumor-targeting vaccines or other therapeutic modalities.
Keywords: immunosuppression; myeloid derived suppressor cells (MDSC); regulatory T cells (Tregs); sCD40L; vaccine therapy.